Wedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $17

Benzinga Newsdesk www.benzinga.com Positive 59.0%

Neg 0% Neu 0% Pos 59%

Wedbush analyst David Nierengarten maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and raises the price target from $12 to $17.